BioMarin Pharmaceutical Inc. (BMRN)

BioMarin Inks $490M Deal to Buy Rare Bone Disease Treatment

BioMarin to acquire Alesta Therapeutics for $275 million for potential rare bone disease treatment

Here Are Wednesday’s Top Wall Street Analyst Research Calls: Baidu, Ciena, CME Group, Dollar Tree, Dominion, Fabrinet, Honeywell Aerospace, Klarna, Pershing Square, and More

BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline

Is BioMarin Pharmaceutical (BMRN) Outperforming Other Medical Stocks This Year?

5 Undervalued Price-to-Book Stocks Worth Buying in August

BMRN vs. ILMN: Which Stock Is the Better Value Option?

Wall Street Analysts See a 28.2% Upside in BioMarin (BMRN): Can the Stock Really Move This High?

Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term

BioMarin Pharmaceutical Inc. (BMRN) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript

BioMarin Targets Faster Deleveraging as Amicus Deal Expands Rare-Disease Growth

BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston

BMRN Stock Up as Q2 Earnings Beat on Sales Growth, 2026 Outlook Raised

BioMarin Pharmaceutical Inc. (BMRN) Q2 2026 Earnings Call Transcript

Compared to Estimates, BioMarin (BMRN) Q2 Earnings: A Look at Key Metrics

BioMarin Pharmaceutical Q2 Earnings Call Highlights

BioMarin Pharmaceutical (BMRN) Surpasses Q2 Earnings and Revenue Estimates

BioMarin Reports Second Quarter 2026 Financial and Operating Results

Amundi Cuts Position in BioMarin Pharmaceutical Inc. $BMRN

BioMarin to Host Second Quarter 2026 Financial Results Conference Call and Webcast on Thursday, August 6, 2026, at 4:30pm ET